Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Applying trial-derived treatment effects to real-world populations: how to estimate cost-effectiveness when modelling complex hazards

Ian Koblbauer, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford

General Research Seminars

Thursday, 08 September 2022, 2pm to 3pm

Hosted by HERC

Date and Time: Thursday 08 September 2022, 2:00 pm (UK BST)

To Join: This is a free event, which will be taking place online via Zoom. To register your interest in attending this talk please click HERE

Abstract: Generalisability of trial-based evidence to real-world target populations is important for decision making. In the context of independent aggregate time-to-event baseline and relative effects data, complex hazards can make modelling of data for use in economic evaluation challenging. Ian will present an overview of approaches for applying trial-derived relative treatment effects to external real-world baselines, and how they can impact cost-effectiveness estimates using an example cost-effectiveness analysis of Head and Neck Cancer treatments.

Biography: Ian is a Clarendon Scholar studying at the Centre for Statistics in Medicine and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford. His DPhil is investigating the use of observational data alongside clinical trials to inform health economic evaluation, including methods to derive comparative effectiveness and other parameter estimates from routinely collected data for use in cost-effectiveness analysis. He has previously worked in consulting and research roles for the pharmaceutical industry and NHS.

Forthcoming External Talks

OxTalks (Oxford Population Health)